News - Mergers & Acquisitions, Novartis, Pharmaceutical

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly


In what looks like a significant restructuring of company focuses, Swiss drug major Novartis and UK peer…

Eli LillyGlaxoSmithKlineMergers & AcquisitionsNovartisPharmaceuticalVaccines

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus


Hong Kong-listed Lansen Pharmaceutical has acquired the pharmaceutical product, marketed and sold in…

Asia-PacificChinaDermatologicalsLansen PharmaceuticalMergers & AcquisitionsNovartisPharmaceuticalSicorten

Retrophin to acquire Kyalin Biosciences; in-licenses Syntocinon


In a second takeover bid within a matter of months, USA-based Retrophin announced that it will acquire…

Kyalin BiosciencesLicensingMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalRetrophinSyntocinonWomen's Health

Novartis sells blood transfusion diagnostics unit to Grifols for $1.675 billion

Novartis sells blood transfusion diagnostics unit to Grifols for $1.675 billion


Swiss drug major Novartis says it is divesting its blood transfusion diagnostics unit to Spain’s Grifols…

GrifolsMergers & AcquisitionsNovartisPharmaceutical

Clinigen acquires oncology support therapy Cardioxane from Novartis


UK-based Clinigen Group (LSE: CLIN) says it has acquired (AIM: CLIN) the oncology support therapy Cardioxane…

CardioxaneClinigen GroupGlobalMergers & AcquisitionsNovartisOncologyPharmaceutical

News briefs from Sanofi, Bayer, GlaxoSmithKline and Novartis


French drug major Sanofi (Euronext: SAN) has entered into a binding agreement to acquire the animal health…

BayerDosch PharmaceuticalsExjadeFlonaseGlaxoSmithKlineLegalMergers & AcquisitionsMerialNovartisOncologyPharmaceuticalregorafenibRegulationRespiratory and PulmonarySanofi

News briefs: Drug majors eyeing Strides Arcolab unit; Astellas invests in oncology facility


Leading drug multinationals, including global behemoth Pfizer (NYSE: PFE) and Swiss major Novartis (NOVN:…

Agila SpecialitesAstellas PharmaGenericsHospiraMergers & AcquisitionsNovartisPfizerPharmaceuticalProductionStrides Arcolab

US FTC puts conditions on Novartis buy of Fougera


The USA's Federal Trade Commission said yesterday that it will require Swiss drug major drug Novartis…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalTolmar

Novartis to buy US generic derma company Fougera for over $1.5 billion


Further expanding its generic drug foot print, Swiss drug giant Novartis (NOVN: VX) is adding to its…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNovartisPharmaceuticalSandoz

Cushing’s syndrome patients to receive safer drug options


New upcoming treatments for Cushing’s syndrome promise to improve patient’s quality of life,…

Corcept TherapeuticsHRA PharmaKorlymMergers & AcquisitionsMifedrenNovartisPharmaceuticalRare diseasesResearchSignifor

Sanofi to top Pfizer as number one for global pharma sales


French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

Proteon Thera gets new funding of $15 million, ahead of Novartis acquisition option


US privately-held biopharmaceutical firm Proteon Therapeutics, the subject of a takeover option by Swiss…

BiotechnologyFinancialMergers & AcquisitionsNovartisPharmaceuticalProteon TherapeuticsResearch

Back to top